{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-244683","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.726417+00:00","generated_at":"2026-06-29T13:01:04.773592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atea reports Q2 net income $1.5M; AT-527 lung data positive, Phase 3 data due 2H21","bullets":["Net income $1.5M vs net loss $10.0M YoY; collaboration revenue $60.4M from Roche.","Cash $816.5M at June 30; $50M Roche milestone payment received in July 2021.","AT-527 active metabolite achieved target antiviral levels in lung lining fluid in healthy volunteers.","Phase 2 interim showed 0.7 log10 greater viral load reduction vs placebo at Day 2.","Phase 3 MORNINGSKY and Phase 2 MOONSONG top-line results expected in 2H 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-244683","json":"https://secwatch.observer/filing/0001193125-21-244683.json","markdown":"https://secwatch.observer/filing/0001193125-21-244683.md","text":"https://secwatch.observer/filing/0001193125-21-244683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312521244683/0001193125-21-244683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312521244683/d360425d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:01:04.773592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}